Free Trial

Gossamer Bio (GOSS) Stock Forecast & Price Target

Gossamer Bio logo
$0.88
-0.01 (-1.13%)
(As of 11/5/2024 ET)

Gossamer Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
5

Based on 5 Wall Street analysts who have issued ratings for Gossamer Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for GOSS.

Consensus Price Target

$9.20
948.43% Upside
According to the 5 analysts' twelve-month price targets for Gossamer Bio, the average price target is $9.20. The highest price target for GOSS is $15.00, while the lowest price target for GOSS is $4.00. The average price target represents a forecasted upside of 948.43% from the current price of $0.88.
Get the Latest News and Ratings for GOSS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gossamer Bio and its competitors.

Sign Up

GOSS Analyst Ratings Over Time

TypeCurrent Forecast
11/6/23 to 11/5/24
1 Month Ago
10/7/23 to 10/6/24
3 Months Ago
8/8/23 to 8/7/24
1 Year Ago
11/6/22 to 11/6/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.20$9.20$9.20$5.48
Forecasted Upside948.43% Upside759.81% Upside1,032.87% Upside838.30% Upside
Consensus Rating
Buy
Buy
Buy
Hold

GOSS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GOSS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gossamer Bio Stock vs. The Competition

TypeGossamer BioMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.79
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside938.02% Upside16,383.90% Upside10.47% Upside
News Sentiment Rating
Very Positive News

See Recent GOSS News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/17/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00+985.53%
8/13/2024Wedbush
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00+403.14%
6/25/2024Oppenheimer
3 of 5 stars
 Initiated CoverageOutperform$9.00+989.44%
6/17/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+1,316.41%
3/27/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$15.00+1,204.34%
7/27/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$8.00 ➝ $1.25-0.79%
3/21/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$2.00 ➝ $1.50+23.97%
3/7/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$5.00+187.36%
2/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
12/12/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$7.00+241.46%
12/7/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$15.00 ➝ $7.00+264.58%
12/7/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
12/7/2022Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$3.00+27.12%
12/7/2022Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$15.00 ➝ $10.00+323.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:48 PM ET.


GOSS Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Gossamer Bio is $9.20, with a high forecast of $15.00 and a low forecast of $4.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOSS shares.

According to analysts, Gossamer Bio's stock has a predicted upside of 948.43% based on their 12-month stock forecasts.

Gossamer Bio has been rated by research analysts at HC Wainwright, and Wedbush in the past 90 days.

Analysts like Gossamer Bio more than other "medical" companies. The consensus rating for Gossamer Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GOSS compares to other companies.


This page (NASDAQ:GOSS) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners